Previous 10 | Next 10 |
IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort - Observed early clinical efficacy in first cohort of darovasertib plus crizotinib combination with tumor reduction in 2 of ...
IDEAYA to Participate in Upcoming May 2021 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , May 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to ...
IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 PR Newswire SOUTH SAN FRANCISCO, Calif. , April 19, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision...
IDEAYA Biosciences (IDYA) announces clinical data from ongoing Phase 1/2 trial evaluating darovasertib (IDE196) monotherapy and binimetinib combination therapy in patients with solid tumors, including Metastatic Uveal Melanoma ((MUM)) and Skin Melanoma.Darovasertib monotherapy preliminary res...
IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma - Darovasertib monotherapy results in 57% 1-year Overall Survival (OS) Rate in predominantly 2L / 3L and heavily pr...
Gainers: [[PGNY]] +7.9%. [[XELB]] +7.0%. [[IDYA]] +6.9%. [[LSCC]] +6.6%. [[DKNG]] +6.0%.Losers: [[SPNE]] -3.8%. [[DBVT]] -3.4%. [[SYBX]] -3.0%. [[SESN]] -2.6%. [[DSEY]] -2.5%. For further details see: PGNY, XELB, SPNE and SYBX among after-hours movers
IDEAYA Biosciences (IDYA) has spiked as much as ~7.0% in the post-market after announcing a pre-market press release and a webcast scheduled for tomorrow to discuss the clinical data from a clinical study involving patients with metastatic uveal melanoma (MUM), a type of...
IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma PR Newswire SOUTH SAN FRANCISCO, Calif. , April 15, 2021 /PRNewswire/ -- IDEAYA B...
IDEAYA Biosciences (IDYA) has begun dosing the first patient in a Phase 1 trial for its experimental cancer therapy IDE397 in patients with solid tumors with methylthioadenosine (“MTAP”) phosphorylase (MTAP) deletion.IDE397 has received IND clearance from the FDA ...
IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors - IDE397 demonstrates significant single-agent anti-tumor activity in a 40-plus MTAP-deletion PDX study, including tumor regressions, across major s...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...
2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...